Birch bark extract as therapy for chronic hepatitis C – A pilot study

Saint Petersburg State Medical Academy named after I.I. Mechnikov, 47, Piskarevsky pr., 195067 Saint Petersburg, Russia.
Phytomedicine: international journal of phytotherapy and phytopharmacology (Impact Factor: 3.13). 03/2011; 18(10):807-10. DOI: 10.1016/j.phymed.2011.01.021
Source: PubMed


The hepatoprotective effect of birch bark extract (BBE) in patients with chronic hepatitis C (CHC) was studied. Forty-two patients with serologically confirmed chronic hepatitis C were treated for 12 weeks with 160 mg standardized BBE per day. The primary outcome parameter measured was the rate of alanine aminotransferase (ALT) normalization after 12 weeks. Secondary parameters included the course of ALT, aspartate aminotransferase (AST) levels, quantitative HCV RNA levels, subjective symptoms associated with CHC (fatigue, abdominal discomfort, depression, and dyspepsia), safety and compliance. The qualitative-quantitative analysis of BBE was made using high performance liquid chromatography to confirm the presence of 75% betulin and 3.5% betulinic acid. Significant differences in the mean ALT and HCV RNA levels were observed after 12 weeks of treatment. The level of ALT was decreased in 54.0% and normalized (p=0.046). HCV RNA was reduced in 43.2% (p=0.016). After 12 weeks of treatment, reports of fatigue and abdominal discomfort were reduced by 6-fold (p=0.028) and 3-fold (p=0.05), respectively. Dyspepsia was no longer reported (p=0.042) and the effect was significantly different from baseline. Because this study lacks a control group clinical relevance of the data can only be estimated in future by following controlled clinical trials.

Download full-text


Available from: Alexander N Shikov, Oct 16, 2014
61 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In order to evaluate the content of betulin and betulinic acids in Birch barks originating from Western Carpathians, Transylvania (Romania) forests, in relation with the location of birch trees, it was recorded the geographic and vegetation conditions at the specific locations of each type of sample. Two groups of birch tree bark (totally 10 samples) were collected, from two regions, pasture surfaces where birch trees appeared spontaneously (samples 1 to 5) and another group from forests of combined trees, including mainly pine trees (samples 6 to 10). The identification and quantitation of betulin and betulinic acid were made by High Performance Liquid Chromatography with UV detection. In the first region it has been found mean concentrations of 126.85 ± 12.56 mg/g betulin bark while acid betulinic had average values of 12.78 ± 1.26 mg/g bark. In the second region we found mean concentrations of 89.84 ± 8.43 mg/g betulin of bark while acid betulinic had average values of 10.60 ± 0.97 mg/g bark. Statistically, significant differences were noticed between the two regions, the first region being richer in these molecules. Generally, the percentage of betulinic acid was around 11.23% against betulin, higher in the second region, even the absolute concentrations were lower for both molecules. These data are useful indicators of the potential offered by birch bark sources found in Transylvania region, to obtain extracts enriched in betulin and betulinic acid.
    Notulae Botanicae Horti Agrobotanici Cluj-Napoca 01/2012; 40(2). · 0.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Because of their selective cytotoxicity against many different tumor cell and their favorable therapeutic index, betuline, betulinic acid and many of their derivatives are very promising chemotherapeutic agents for the treatment and prevention of several diseases especially of cancer. © 2012 Springer Science+Business Media Dordrecht. All rights are reserved.
    Novel Apoptotic Regulators in Carcinogenesis, 01/2012: pages 267-287; , ISBN: 978-94-007-4916-0
  • [Show abstract] [Hide abstract]
    ABSTRACT: Till date the synthetic hepato-protective agents used in clinical practices are therapeutically non-promising and may itself lead to hepatotoxicity. Herbal medicines and their bioactives are considered to be relatively safe and have been used in the treatment of liver diseases for a long time. The 21st century has seen a paradigm shift towards therapeutic standardization of herbal drugs in hepatic disorders by evidence-based randomized controlled clinical trials to support their clinical efficacy. Even so, the specific hepato-protective clinical trial protocols for herbal medicines are not established till now. So, the efficacy of herbal medicines needs to be evaluated through rigorously designed multicentre clinical studies. In this review, we have enlightened the clinically evaluated hepatoprotective herbals and herbal formulations with respect to their status in different trial stages. Moreover, the problems and their strategic solutions during the development of clinical trial protocol for hepatoprotective herbal medicine are also addressed.
    Reviews on Recent Clinical Trials 04/2012; 7(3):214-23. DOI:10.2174/157488712802281240 · 1.07 Impact Factor
Show more